DRIO vs LLY

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -17. 3% for DarioHealth Corp. (DRIO). DarioHealth Corp. (DRIO) offers the better valuation at 5. 6x trailing P/E, making it the more compelling value choice. Analysts rate DarioHealth Corp. (DRIO) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, DarioHealth Corp.

(DRIO) is the cheapest at 5. 6x versus Eli Lilly and Company at 47. 8x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +413.

8%, compared to -98. 4% for DarioHealth Corp. (DRIO). Over 10 years, the gap is even starker: LLY returned +1450% versus DRIO's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), DarioHealth Corp.

(DRIO) is the lower-risk stock at 0. 35β versus Eli Lilly and Company's 0. 52β — meaning LLY is approximately 47% more volatile than DRIO relative to the S&P 500. On balance sheet safety, DarioHealth Corp. (DRIO) carries a lower debt/equity ratio of 47% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -17. 3% for DarioHealth Corp. (DRIO). On earnings-per-share growth, the picture is similar: DarioHealth Corp. grew EPS 267. 6% year-over-year, compared to 96. 0% for Eli Lilly and Company. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -186. 6% for DarioHealth Corp. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -163. 9% for DRIO. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DRIO: 80.

4% to $12. 50.

In this comparison, LLY (0.

5% yield) pays a dividend. DRIO does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 0. 5% yield, +1450% 10Y return). Both have compounded well over 10 years (LLY: +1450%, DRIO: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DRIO is a small-cap deep-value stock; LLY is a mega-cap high-growth stock. LLY pays a dividend while DRIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.